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http://dx.doi.org/10.1016/j.pedneo.2Enterovirus 71 (EV71) was first described in USA in 1969 but retrospective studies in The
Netherlands further detected EV71 in the clinical specimens collected in 1963. EV71 has one
single serotype measured by using hyperimmune animal antisera but can be phylogenetically
classified into three genogroups (A, B, and C) including 11 genotypes (A, B1eB5, C1eC5). In
Taiwan, EV71 caused a large-scale nationwide epidemic in 1998. Retrospective studies further
detected EV71 in clinical specimens collected from handefootemouth disease patients in 1980
and 1986. Therefore, EV71 may have circulated in Taiwan prior to 1980. Since 1998, EV71 has
cyclically caused nationwide epidemics with different predominant genotypes in 1998 (geno-
type C2), 2000e2001 (B4), 2005 (C4), 2008 (B5), and 2012 (B5). Phylogenetic analysis revealed
that C4 viruses isolated in 2005 were probably from China, B5 viruses isolated in 2008 were
probably from South Eastern Asia, and B5 viruses isolated in 2012 were probably from Xiamen,
China. Several studies have collected postinfection sera from children to measure cross-
reactive neutralizing antibody titers against different EV71 genotypes and found that antigenic
differences between genogroup B and C viruses did not have a clear pattern but that genotype
A virus was antigenically different from genogroup B and C viruses. In conclusion, EV71 cycli-
cally caused nationwide epidemics through international importations. EV71 surveillance in
Taiwan should combine genetic and serological methods.
Copyright ª 2013, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.titute of Infectious Diseases
arch Institutes, Taiwan.
(M.-S. Lee).
an Pediatric Association. Publish
013.07.0071. Introduction
Enteroviruses (EVs) are single-stranded, positive-sense RNA
viruses in the Picornaviridae family. They cause various
clinical manifestations, including cutaneous, visceral, and
neurological diseases.1 Human EV can be further classifieded by Elsevier Taiwan LLC. All rights reserved.
Table 1 Laboratory diagnosis methods for recent EV71
infections.
244 M.-Y. Chia et alinto four species including human EV A (20 serotypes such as
EV71 and coxsackievirus A), human EV B (59 serotypes),
human EV C (21 serotypes), and human EV D (4 serotypes).
Overall, human EV has more than 100 serotypes.1,2 For
many years, polioviruses were the most important EVs
because they caused large outbreaks of paralytic disease
before poliovirus vaccines were available. EV71 was first
described in California, USA, in 1969. Since then, EV71 has
been detected worldwide.2e5 Globally, two patterns of
EV71 epidemic have been reported: small-scale outbreaks
with few central nervous system (CNS)-complicated cases
and deaths, and large-scale outbreaks with frequent CNS-
complicated cases and deaths. The latter pattern
occurred in Bulgaria (1975), in Hungary (1978), in Malaysia
(1997), in Taiwan (1998), in Singapore (2000), in southern
Vietnam (2005, 2007e2009, and 2011), in Brunei (2006), in
Korea (2009), and in China (2007e2009).2,6 Because EV71
mortality rates are heavily affected by healthcare acces-
sibility and standards, a more relevant clinical definition,
such as CNS complication should be also used to quantify
disease burden of EV71 infections in prevalent areas.
Although EV71 was first isolated in 1969, a retrospective
analysis shows that this virus circulated in The Netherlands
as early as 1963.5 Molecular evolution studies further pre-
dicted that EV71 could have emerged in the human popu-
lation around 1941.5,7 Recently, EV71 repeatedly caused
life-threatening outbreaks of handefootemouth disease
(HFMD) with neurological complications in Asian children.
The neurological manifestations progress very quickly and
range from aseptic meningitis to acute flaccid paralysis and
brainstem encephalitis.2 Due to its tremendous impact on
healthcare systems, development of EV71 vaccines is a
national priority in Taiwan and other Asian countries.
Several vaccine candidates are being evaluated in humans
and some will be licensed in the near future. Epidemio-
logical characteristics are critical to the design of vaccine
trials and formulation of vaccination policy when vaccines
are licensed. Therefore, this review will focus on epide-
miology of EV71 infections in Taiwan.Method Advantages Disadvantages
Virus isolation/IFA Provide virus
isolates
for further study
Low sensitivity
Time consuming
Requires skillful
manpower
Nested RT-PCR High sensitivity
Time-saving
Requires skillful
manpower
False positivity
Multiple primers for
different genotypes
CODEHOP RT-PCR High sensitivity
Time saving
Requires skillful
manpower
Requires sequencing
Serology:
neutralizing
antibody
High sensitivity
High specificity
Requires skillful
manpower
Requires pair sera
Serology: ELISA
IgM
Rapid diagnosis False positivity
ELISA Z enzyme-linked immunosorbent assay;
IFA Z immunofluorescence assay; RT-PCR Z reverse tran-
scription polymerase chain reaction.2. Clinical spectrum of EV71
According to previous clinical studies conducted in northern
Taiwan, symptomatic EV71 infections progress through four
stages: HFMD/herpangina (Stage 1), CNS involvement
(Stage 2), cardiopulmonary failure (Stage 3), and conva-
lescence (Stage 4).2 This classification was recently rec-
ommended in a World Health Organization (WHO) report.6
Follow-up studies further demonstrated that EV71 infec-
tion can cause long-term sequelae including neurological
development and cognitive function.8 In a prospective
hospital-based case-finding study, 21% of 183 EV71 in-
fections in children aged < 18 months of age developed
neurological complications such as meningitis and enceph-
alitis.9 Based on national severe EV surveillance and two
cross-sectional serological surveys, Lu et al10 estimated
that 130,617 Taiwanese children aged < 3 years were
infected with EV71 infections in 1998 and that 273 (0.21%)
of these infected children developed neurological compli-
cations. Overall, the prospective hospital-based case-
finding study would overestimate the proportion of EV71infections with neurological complications and the national
surveillance data would underestimate the proportion of
EV71 infections with neurological complications. In a cohort
study conducted from 2006 to 2012 in northern Taiwan,
about 100 EV71 primary infections were detected serolog-
ically in children younger than 5 years and none of them
developed neurological complications (Lee MS et al, un-
published data). Therefore, the proportion of EV71 in-
fections with neurological complications would be between
0.21% and 1%.
3. Laboratory diagnosis of recent EV71
infections
EVs include over 100 serotypes and usually cause self-
limited infections with nonspecific symptoms in children,
with the exceptions of polioviruses and EV 71 which
frequently cause neurologic complications. Therefore,
early detection and serotyping of EVs are critical in clinical
management and disease surveillance. Moreover, herpan-
gina and HFMD are major clinical manifestations for EV71
and other EV species A viruses. Therefore, laboratory
diagnosis is critical to differentiate EV71 infections from
other EVs. There are several methods for laboratory diag-
nosis of recent EV71 infections, including viruses isolation,
molecular methods, and serology (Table 1). The traditional
methods for detection and serotyping of EV infections are
virus isolation and immunofluorescence assay, which are
time-consuming and labor-intensive.11,12 Several clinical
studies have documented that molecular diagnosis based on
polymerase chain reaction saves time and is more sensitive
than virus isolation for the detection of EV infections in
hospitalized patients,13e16 but few studies have been con-
ducted on outpatients. Moreover, no study has compared
molecular tests and virus isolation/immunofluorescence
Table 2 EV71-related severe and fatal cases in Taiwan,
1998e2012.
Year Severe
case no.*
Death no.
(case fatality
ratey)
Predominant
genotype
1998 405 78 (19) C2
1999 6 1 (17) B4
2000 152 25 (16) B4
2001 181 27 (15) B4
2002 58 8 (14) B4
2003 44 4 (9) B4
2004 20 5 (25) C4
2005 82 8 (10) C4
2006 2 0 C5
2007 7 2 (29) C5
2008 344 14 (4) B5
2009 25 2 (8) B5
2010 12 0 C4
2011 59 3 (5) C4/B5
2012 144 2 (1) B5
Data are presented as n (%).
Data source: Taiwan Centers for Disease Control.
* Different laboratory methods were used for different years
so these data should be interpreted with caution.
y Case fatality rate Z number of deaths/number of severe
cases.
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Although these methods have been used to detect EVs in
clinical specimens including throat swabs, stool samples,
and cerebrospinal fluid,12e14,16e19 reports elucidating the
comparison among the diagnostic approaches are limited.
Molecular tests for the detection of human EVs in clinical
specimens usually target highly conserved sites in the 50
untranslated region.20 Due to low virus titers in clinical
specimens, several reverse transcription-nested or reverse
transcription-seminested polymerase chain reaction have
been developed to further increase its sensitivity and spe-
cificity.21e23 However, serotyping of EVs based on 50 un-
translated region sequences directly amplified from clinical
specimens have not been well evaluated. In addition, EV VP1
capsid gene has recently been proposed to be an ideal target
for the detection and serotyping of EVs using the consensus
degenerate hybrid oligonucleotide primer (CODEHOP).24 A
recent study compared virus isolation and the two molecular
tests for detection and serotyping of EVs in clinical samples
and found that the VP1 CODEHOP test performed well for
detection and serotyping of EVs in clinical specimens and
that it could reduce unnecessary hospitalization during EV
seasons.25 Although molecular methods are much more
sensitive than the virus isolation for the detection of EV in-
fections, they require skillful manpower and are not suitable
for clinics and community hospitals.
There are two serological methods available for labo-
ratory diagnosis of recent EV71 infections, including
neutralization assay and enzyme-linked immunosorbent
assay (ELISA) immunoglobulin M (IgM). The neutralization
assay is the most reliable method but it requires collection
of pair sera, which is not feasible for most situations.
Several studies have tried to develop ELISA serum IgM
methods for rapid diagnosis of EV71 infections but these
serum IgM assays all share the drawback of frequent false
positive reactions (>20%) in patients infected with other
human EVs such as CVA6 and CVA16 (Lee MS et al. unpub-
lished data).26e28 Serum IgM tests with low false positive
reactions are desirable to reduce unnecessary hospitaliza-
tion during EV seasons.4. EV surveillance in Taiwan
A nationwide EV71 epidemic occurred in Taiwan in 1998,
which may have caused the largest number of severe cases
and deaths in human history. Since then, a national EV sur-
veillance system has been established by Taiwan Centers for
Disease Control. The national EV surveillance system includes
three components: (1) a sentinel physician network to collect
weekly number of HFMD and herpangina, which was recently
replaced by the Real-time Outbreak and Disease Surveillance
through the National Health Insurance Database;29,30 (2) a
laboratory network for virus identification by collecting
throat swabs from EV-like patients (herpangina and HFMD);
and (3) mandatory notification of EV-like severe cases, which
collects throat swab, serum, and contact information through
an epidemiological investigation. Based on these surveillance
data, nationwide EV71 epidemics have occurred cyclically in
Taiwan since 1998 (Table 2). Retrospective studies further
found that EV71 epidemics may have occurred in Taiwan in
1980 and 1986.31,32 As shown in Table 2, the first recognizedEV71 epidemics occurred in 1998 with 405 severe cases
including 78 fatal cases. Nationwideepidemics occurredagain
in 2000e2001, 2005, 2008, and 2012 with different predomi-
nant genotypes. Overall, clinical spectra of these epidemics
were similar although different genotypes predominantly
circulated in different years.32,33 The laboratory diagnosis
methods only employed virus isolation in early years but were
revised to include serum IgM and molecular methods later.
Therefore, it is not feasible to compare themagnitudeof EV71
epidemics based on number of EV71 confirmed severe cases.
However, case fatality rates decreased significantly in recent
years, which may be related to an early warning of EV71 ep-
idemics and stage-based clinical management.6,32
5. Age-specific incidence rates
To design clinical trials of EV71 vaccines, age-specific
incidence rates of EV71 infections are required to identify
target populations, estimate disease burdens, define end-
points of clinical efficacy, and calculate the sample size for
efficacy trials. Age-specific incidence rates of EV71-related
severe infections during the 1998 epidemic have been
estimated to be 27.3/100,000, 37.1/100,000, 30.0/100,000,
and 23.1/100,000 for children aged <6 months, 6e11
months, 12e23 months, and 24e35 months, respectively,
which are too low to be a suitable endpoint of efficacy
trials.34 Alternatively, EV71-related mild illness such as
herpangina and HFMD could be suitable clinical endpoints.
In an infant prospective cohort study initiated in 2006 in
northern Taiwan and employing serum neutralization assay
to detect EV71 infections, the age-specific incidence rates
of EV71 infection during the 2008e2009 epidemic were
observed to increase from 1.71/100 personeyears at age
246 M.-Y. Chia et al0e6 months infants to 4.09/100 personeyears, 5.74/100
personeyears, and 4.97/100 personeyears in children aged
7e12 months, 13e24 months, and 25e36 months, respec-
tively. In addition, the cumulative incidence rate was 15%
by age 36 months, 39% of EV71 infections developed HFMD/
herpangina, and 29% of EV71 infections were asymptomatic
in young children.35 A retrospective serosurvey also found
that 37% of seropositive children reported to develop
HFMD/herpangina during the 1998 nationwide epidemic in
Taiwan.34 Overall, development of EV71 vaccines should
target children age < 6 months, and EV71-related mild
illness such as herpangina and HFMD could be used as the
clinical endpoints of efficacy trials.36
6. Seroprevalence of serum EV71 neutralizing
antibody
In addition to age-specific incidence rates that require
time-consuming prospective cohort studies, seroprevalence
studies of neutralizing antibody can be readily conducted
to estimate cumulative infection rates. Several seropreva-
lence studies have been completed in Taiwan using sera
collected in 1994, 1997, and 1999 (Table 3). Overall, sero-
positive rates of EV71 neutralizing antibody in sera
collected in 1994 were 39% in 5-year-old children and 57% in
8-year-old children, which indicates that EV71 was preva-
lent from 1986 to 1994. Seropositive rates of EV71
neutralizing antibody in children aged <3 years in 1997 in
Taipei City were about 0% (age 0.5e0.9 years) to 15% (age 3
years), which are much lower than in the same age groups
in 1999. In a large-scale cross-sectional serosurvey con-
ducted in 1999 in six areas including two urban (Taipei City
and Kaohsiung City) and four rural areas, seropositive rates
were higher in the preschool children in rural areas than in
the urban areas but similar in school children in both areas,
which indicates more intrafamily transmission affecting
preschool children occurred in rural areas.Table 3 Age-specific seroprevalence of EV71 neutralizing antib
Locationref Year Findings
Taipei city10 1994 39% for 5 y, 57% for 8 y, 67% for 10e20 y
Taipei city10 1997 44% for <6 mo, 0% for 6e11 mo, 5% for 1
Taipei city10 1999 38% for <6 mo, 15% for 6e11 mo, 20% fo
33% for 6 y, 51% for 7 y, 47% for 8 y, 64%
77% for >50 y
Taipei city34 1997 36% for <0.5 y, 4% for 0.5e0.9 y, 4% for
66% for 12e19 y, 57% for 20e29 y
Taipei city34 1999 7% for <0.5 y, 0% for 0.5e0.9 y, 8% for 1
54% for 12e19 y, 60% for 20e29 y, 48% fo
Ilan county34 1999 8% for <0.5 y, 15% for 0.5e0.9 y, 18% for
74% for 12e19 y, 78% for 20e29 y, 50% fo
Taoyuan
county34
1999 13% for <0.5 y, 15% for 0.5e0.9 y, 30% fo
60% for 12e19 y, 55% for 20e29 y, 47% fo
Taichung
county34
1999 12% for <0.5 y, 0% for 0.5e0.9 y, 14% for
81% for 12e19 y, 73% for 20e29 y, 75% fo
Kaohsiung
city34
1999 10% for <0.5 y, 3% for 0.5e0.9 y, 5% for
56% for 12e19 y, 58% for 20e29 y, 72% fo
Kaohsiung
county34
1999 24% for <0.5 y, 9% for 0.5e0.9 y, 12% for
68% for 12e19 y, 63% for 20e29 y, 67% fo7. Genetic and antigenic evolutions
According to analysis of VP1 sequences, EV71 was phyloge-
netically divided into three distinct genogroups: A, B, and
C.1,2 Genogroups B and C can be further divided into geno-
types B1eB5 and C1eC5, respectively, and genotype C4 is
further classified into subgenotypes C4a and C4b.36
Recently, genogroups D, E, and F were identified in India.37
Genogroup A includes the EV71 strain (BrCr-CA-70), which
was identified in 1970 in the USA but was not detected again
until 2008. In an investigation of the HFMD outbreak in Anhui,
China in 2008, five EV71 isolates were identified and they
were closely related to genotype A based on analysis of VP1
genes.38 In 2009, genotype Aviruseswere further detected in
Beijing, Hubei, and Yunan (Figure 1). Reasons for the re-
emergence of genotype A in China are not clear and should
be clarified. By contrast, genotypes B and C continued to
circulate around the world after the 1970s and the 1980s,
respectively. Recently, retrospective studies have shown
that a genotype B0 virus circulated in The Netherlands as
early as 1963 and a genotype C0 virus circulated in Japan as
early as 1978.4,5 Interestingly, genogroup B viruses seemed
to evolve through positive selection and only genotype B5
viruses are circulating. By contrast, genogroup C viruses
have evolved through neutral selection and multiple geno-
type C viruses including C2, C4, and C5 are cocirculating
globally.5,7,36 Moreover, EVs frequently recombine to
generate new genotypes and serotypes, which could only be
elucidated by complete genome analysis. Therefore, more
efforts are required to generate complete genome data
especially early EVs isolated before 1980.
In Taiwan, different predominant genotypes were iden-
tified in different epidemics (Table 2; Figure 1). Based on
retrospective studies, genotype B1 viruses circulated in
Taiwan from 1980 to 1986. In the 1970s, genotype B1 viruses
circulated widely in Europe, Japan, and USA. Phylogenetic
analysis of VP4 genes found that the genotype B1 virusesody in Taiwan.
, 58% for 31e50 y
y, 16% for 2 y, 15% for 3 y, 38% for 5 y, 47% for 10e20 y
r 1 y, 22% for 2 y, 21% for 3 y, 29% for 4 y, 29% for 5 y,
for 9 y, 63% for 10e20 y, 69% for 21e30 y, 69% for 31e50 y,
1e1.9 y, 22% for 2e2.9 y, 36% for 3e5.9 y, 63% for 6e11 y,
e1.9 y, 11% for 2e2.9 y, 34% for 3e5.9 y, 56% for 6e11 y,
r 30e49
1e1.9 y, 15% for 2e2.9 y, 49% for 3e5.9 y, 79% for 6e11 y,
r 30e49 y
r 1e1.9 y, 36% for 2e2.9 y, 49% for 3e5.9 y, 58% for 6e11 y,
r 30e49 y
1e1.9 y, 30% for 2e2.9 y, 51% for 3e5.9 y, 65% for 6e11 y,
r 30e49 y
1e1.9 y, 15% for 2e2.9 y, 26% for 3e5.9 y, 57% for 6e11 y,
r 30e49 y
1e1.9 y, 25% for 2e2.9 y, 40% for 3e5.9 y, 61% for 6e11 y,
r 30e49 y
 C4a-KF154310-00184-TW-2012
 C4a-KF154293-01585-TW-2011
 C4a-JX986739-Wuhan1143-HuB-CHN-2011
 C4a-KF154356-00704-TW-2010
 C4a-AY905614-ZJ-CHN-1-CHN-2003
 C4a-GQ231932-TW-2871-TW-2004
 C4b-AB465409-763/Toyama-JPN-1997
 C4b-EU131776-N3340-TW-2002
 C4b-JN230523-Xiangyang-Hubei-CHN-2009
 C4b-AF302996-SHZH-CHN-1998
 C3-DQ341355-06-KOR-2000
 C1-AF135945-2623-AUS-1986
 C1-JN874553-4215-TW-1998
 C1-FJ868281-20.2.04-TW-2004
 C5-AM490161-933V-VNM-2005
 C5-EF063152-E2005125-TW-2006
 C5-KC222965-HCM84-VNM-2011
 C5-HQ676173-FI11/ns/T/09-Finland-2009
 C5-EU527983-07364-TW-2007
 C2L-HM622391-00643-TW-2008
 C2-EV71-AB665746-JPN-2010
 C2-AF135949-2644-AUS-1995
 C2-AF176044-TW-1998
 A-GU434678-Hubei-CHN-2009
 A-JN408343-10-Yunnan-CHN-2009
 A-U22521-BrCr-USA-1970
 A-JQ410995-CMU3-1-Beijing-CHN-2009
 A-GQ117124-001-Luan-Anhui-CHN-2008
 B2-AF135888-2952-SD-USA-1981
 B2-JQ766157-B27423-CHN-2011
 B1-AB575913-11977-NED-1971
 B1-FJ357380-237-TW-1986
 B3-DQ341367-MY821-3-SAR-MAL-1997
 B3-JQ950555-26M/4/99/GuaR1-AUS-1999
 B4-HQ283893-3351-TW-1999
 B4-GQ150746-E59-TW-2002
 B5-JN316089-PM-11977-MAL-1999
 B5-EU131740-N2838-TW-2003
 B5-JN874552-141-TW-2008
 B5-EU527985-TW-2007
 B5-JN964686-Xiamen-CHN-2009
 B5-KF154308-03939-TW-2011
 B5-KF154353-03419-TW-2012
 CVA16-U05876-G-16-RSA-1951
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Figure 1 Phylogenetic analysis of VP1 genes of representative EV71 strains. The phylogenetic tree was generated by the
neighbor-joining method with 1000 bootstraps based on nucleotide sequence from 2481 to 3278 using genome of EV71 (accession
number is U22521) as reference. Only bootstrap values over 70% are shown. Coxsackievirus A16 strain was used as the outlier.
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248 M.-Y. Chia et alisolated in Taiwan in 1980 and 1986 clusters together but
could be differentiated from other genotype B1 viruses,
which indicates that genotype B1 viruses have been intro-
duced to Taiwan for some time.31 Information about circu-
lating genotypes is not available from1987 to 1997 in Taiwan.
In 1998, Taiwan experienced the largest epidemic caused by
genotype C2. Genotype C2 viruses were widely detected in
the middle 1990s in Australia, Japan, and The Netherlands
and they were likely to have emerged though recombination
between EV71 and CAV8.39 The genotype C2 viruses were
replaced by genotype B4 viruses, which caused nationwide
epidemics in 2000e2001 in Taiwan. Genotype B4 viruses
werewidely detected in the late 1990s and could evolve from
genotype B2 viruses. The B4 viruses were replaced by geno-
type C4a viruses, which caused nationwide epidemics in
2005. Genotype C4 viruses were first detected in Japan and
China in 1997 and 1998, respectively and evolved into two
subgenotypes (C4b and C4a) in 2003 (Figure 1). Since then,
genotype C4a viruses have become predominant and spread
to a lot of countries including Australia, Austria, Japan,
Taiwan, and Vietnam. Genotype C4a viruses could evolve
from recombination between genotype C4b and genogroup B
viruses. The genotype C4a viruses were replaced by geno-
type C5 viruses, which only spread sporadically in 2006e2007
in Taiwan. Genotype C5 viruses were first detected in Viet-
nam in 2003 and caused a large scale of epidemic in 2005.40
Genotype B5 viruses emerged in late 2007 in Taiwan and
caused a nationwide epidemic in 2008. Genotype B5 viruses
were first detected in South Asia (Singapore or Malaysia) in
1999 and spread to several Asian countries in the early 2000s
(Figure 1). In 2003, genotype B5 viruses were detected
sporadically in Taiwan. They were not detected again in
Taiwan until 2007. After the 2008e2009 epidemic, genotype
B5 viruses disappeared and only genotype C4a viruses were
detected sporadically in 2010 and 2011 in Taiwan. Genotype
B5 viruses re-emerged in mid-2011 in Taiwan and caused
nationwide outbreaks in 2012. Interestingly, the re-emerging
genotype B5 viruses in 2011e2012 were phylogenetically
closer to B5 viruses circulated in Xiamen, China in 2009 than
to the B5 viruses isolated in Taiwan in 2008e2009 (Figure 1;
Lee MS et al, unpublished data). International spreading of
EV71 is common in Asia and should be monitored through
international networks.
Because EV71 genetic variants have beenwidely identified
in Taiwan and globally, it is necessary to examine their anti-
genic variations, which is critical to the selection of vaccine
strains. EV71 has one single serotype as measured by using
hyperimmune animal antiserum but antigenic variations have
been reported recently in human studies. Using sera collected
from young children with a primary infection of genotype B5,
two studies detected partial antigenic differences between
genogroups B and C but not between viruses in the same
genogroup (B5 and B4 viruses).18,33 Kung et al41 did not detect
significant antigenic differences between genotypes B4 and
C4 viruses using acute-phase sera from EV71 inpatients. A
serological survey in healthy Japanese children and adults
detected partial antigenic differences between genotype B5
andAvirusesbutnotamongdifferentgenotypes ingenogroups
B and C that had previously circulated in Japan.42 By con-
structing an antigenic map, however, Huang et al43 detected
antigenic differences between genogroups B and C, and also
between B5 and B4 viruses. A recent study found thatTaiwanese children infected with genotypes C2, C4, B4, and
B5 had lower GMTs (4-fold difference) against genotype A
than other genotypes but antigenic variations between gen-
ogroups B and C did not have a clear pattern.44 It is hard to
compare different studies that employed different human
sera and laboratory procedures, in particular the cell lines
used in the neutralization assay. A network to harmonize
laboratory procedures including standard sera and viruses is
required to make the comparison possible. Moreover, the
clinical and epidemiological significance of the observed
antigenic variation requires longitudinal serological studies
for clarification. In addition, it is not feasible to collect a large
amount of serum from children postinfection to measure
cross-reactive neutralizing antibody titers against multiple
EV71 genotypes. Recently, a rabbitmodel has beendeveloped
to generate antisera for monitoring antigenic variations of
EV71, which could be integrated to EV surveillance system
(Lee MS, unpublished data).8. Conclusions
EV71 is highly contagious and causes life-threatening out-
breaks in children in Taiwan and several Asian countries. In
the past 10 years, EV71 has caused nationwide epidemics
every 3e4 years in Taiwan. Different genotypes dominate in
different epidemics but the pattern is not predictable in
Taiwan. Case-fatality rates of EV71 infections in recent
epidemics seem to decrease significantly in Taiwan due to
early warning of EV71 epidemics and stage-based clinical
management. Overall, EV71 seems to have evolved rapidly
and spread widely in Asia in the past 15 years. The Taiwa-
nese experience on control and prevention of EV71 would
be valuable to other countries facing EV71 epidemics.Conflicts of interest
The authors have no conflicts of interest relevant to this
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